Therefore, the concurrent expression of CD27 and EGFR in various epithelial cancers, along with the gene expression signatures related to exhaustion, cytotoxicity, and tissue residency of CD27-expressing T cells, underscores the potential of EGFR-targeted activation of CD27 agonism for enhancing the re-activation of tumor-infiltrated and tumor-reactive T cells in EGFR-expressing cancers. The gene discussed is EGFR; the disease is neoplasm.